SCDATA | GCPS System

Dream Job Analysis (Procurement and Buyer Roles in Pharmaceutical Supply Chains)

A Macro-to-Micro Evaluation of Career Resilience.

"The project determines an ideal career in the pharmaceutical manufacturing industry in the U.S. through the analysis of the opportunities in three perspectives namely, the regional economic health, industry development, and the financial stability of the company. The analysis examines the functions of procurement and buyers that facilitate pharmaceutical supply chains and assess the resilience and strategic value of these functions in the long run."

Ujjwal Gandhi

Senior, Supply Chain Management

Procurement & Buyer Career Focus

USA

1

1/8

The Roadmap

Region: Determine the U.S. states as having the greatest pharmaceutical manufacturing and supply chain activity, including regions that provide good procurement and career buyer opportunities.
Industry: Compare the pharmaceutical manufacturing industry and the overall Industrials industry on grounds of profitability, growth and financial risk.
Company: Evaluate the financial stability of companies and the strength of their employees through profit, ratios of returns on assets (ROA) and leverage ratios, such as liabilities/assets.
Summary: Generalize the regional, industry, and company-specific information to identify the most robust and desirable career within the field of procurement and buyer functions in the pharmaceutical supply chains.

2

2/8

Analysis and visualization

3

This enterprise distribution analysis indicates that manufacturing of pharmaceuticals in the United States is very concentrated on few states. The number of pharmaceutical enterprises is greatest in California and the rest states like New Jersey, Texas, Massachusetts, and Pennsylvania. The advantages of these states are good manufacturing facilities, availability of R&D and skilled labor.

In the case of procurement and buyer positions, this level of concentration is vital in that it forms an unremitting demand to source out active pharmaceutical ingredients (APIs), raw materials, packaging, and contract manufacturing services. Areas characterized by high pharmaceutical concentration are better in terms of career security, supplier bases, and strategic procurement participation prospects.

3/8

Regional Notes & Insights

United States

These statistics indicate that the production of pharmaceuticals in the United States is highly concentrated in few states. California is way ahead of the pack with prominent centers like New Jersey, Massachusetts, Texas and Pennsylvania coming in second. The main hubs of the operations of the pharmaceutical supply chain are these states, as they enjoy a good manufacturing infrastructure, research and development ecosystems, as well as availability of the skilled labor.

2026 Insight

In the future, such developed pharmaceutical centers are supposed to stay on the top, as further investment in drug-production, in home-based production, and the stable demand results of the regulations are predicted. In the case of procurement and buyer, the highest density of enterprises in the states gives the highest stability of employment opportunities and better scope of supplier connections and exposure to the strategic sourcing decision in the pharmaceutical supply chain.

4

4/8

Industrial Trend - Profitability

5

5/8

Industry Notes & Insights

2024 Fact

The pharmaceutical manufacturing sector was reported to be highly profitable and financially stable in 2024 than the overall Industrials sector. Constant demand of necessities in the form of medicines, entry barriers by means of regulation and continuous investment in research and development sustained steady margins as the wider economy was uncertain.

2026 Insight

With a view to 2026, the industry of pharmaceutical manufacture is projected to experience the positive impact of the development of domestic production, the emphasis on the resilience of a supply chain, and the maintenance of the healthcare demand. These patterns support the strategic value of procurement and buyer functions especially when it comes to sourcing active pharmaceutical ingredients (APIs) and supplier risk management as well as obtaining long-term contracts. This makes the pharmaceutical industry a livelier and more attractive career choice as compared to the Industrials in case of supply chain professionals with procurement in mind.

6

6/8

Company Notes & Insights (No Visualization)

The Winner

Because of the limitation on the availability of data in the visualisation tool, it was necessary to engage in a qualitative financial comparison based on industry-level indicators. Major American pharmaceutical companies like AbbVie, Pfizer, and Johnson and Johnson have been showing good profitability, huge assets, and well-balanced balance sheets.
These companies have effective uses of assets (high ROA) and manageable ratios of liabilities-to-assets, which means that they have less financial risk. This financial capability allows them to invest in procurement activities in the long-term, diversify suppliers and have long-term sourcing contracts.

2026 Insight

As of 2026, the pharmaceutical companies will have enough financial resources to invest more in manufacturing in the country, resilience of API sourcing, and risk removal with suppliers. This makes the strategic value of procurement and buyer activities and these firms the most secure and the best place to work as a supply chain professional.

7

7/8

Summary & Conclusion

A Procurement or Strategic Sourcing opportunity in the U.S. pharmaceutical manufacturing sector is my future dream career in 2026. The career choice was determined by assessing opportunities on the three main prisms including the economic power of the region, industry profitability, and financial stability of the companies.
To start with, the United States with its concentration of pharmaceutical production, research centers, and supplier networks, comes out as the most powerful area, especially in New Jersey, Pennsylvania, Massachusetts, or California. These areas offer high concentration of employment as well as permanency in careers to supply chain professionals.
Second, the pharmaceutical industry is more profitable and its demand is more standard, unlike the larger Industrials industry, which has a necessity in healthcare, protection of patents, and long-term R&D investment. This renders the industry more resilient in the economic downturns.
Lastly, the major pharmaceutical corporations in the U.S. including AbbVie, Pfizer, and Johnson and Johnson are financially healthy, with huge asset base and sizeable liabilities. They are the most desirable employers because they proved to be efficient in terms of using assets and investing in supply chain resilience.
In general, the U.S. pharmaceutical industry focusing on procurement has the most promising mix of stability, growth and strategic value, and therefore the career of 2026 would be the most suitable one.

8

8/8

Dream Job Analysis - cite from project of BT2611(1)

Dream Job Analysis (Procurement and Buyer Roles in Pharmaceutical Supply Chains)

Primary Modal